TelevisaUnivision is moving aggressively to turn its microdrama platform into a new growth engine, betting that the melodramatic storytelling that powered decades of telenovelas can be reshaped for mobile-first audiences in one- to two-minute vertical episodes.

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.

Elon Musk tweeted about wanting Jurassic Park in real life. Companies aren't bringing back dinosaurs yet, but they are bringing extinct items back to life.

Ginkgo Bioworks reported Q4 revenues of $33 million, down 24% year-over-year, and missing estimates by over $4 million. Cell Engineering, expected to drive growth, delivered just $125 million in 2025 revenue, far below the original $1.1 billion SPAC projection. Management is pivoting by selling the Biosecurity segment, retaining only a minority stake in the new private entity.

BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser.

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript

Ginkgo Bioworks (NYSE: DNA) shares are down following the company's fourth-quarter and full-year 2025 financial report.

Ginkgo provides an update on its fourth quarter financial results BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026 BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costs BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo") and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs. Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chemistry.